Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)
Authors:
Open Access
- 21 August 2025
- journal article
- Published by Elsevier in eClinicalMedicine
- Vol. 87, 103459
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82430010)
- Tianjin science and technology commission (24ZXZSSS00230)
- Tianjin Municipal Science and Technology Committee
- CAMS Innovation Fund for Medical Sciences (2023-I2M-2-007)
- National Major Science and Technology Projects of China (2023ZD0500803)
This publication has 26 references indexed in Scilit:
- Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort StudyAmerican Journal of Hematology, 2024
- Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Haematology, 2024
- Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation CyclophosphamideTransplantation and Cellular Therapy, 2024
- Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopeniaPlatelets, 2023
- Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational studyChinese Medical Journal, 2022
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaNew England Journal of Medicine, 2022
- The incredible journey: From megakaryocyte development to platelet formationJournal of Cell Biology, 2013
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Romiplostim or Standard of Care in Patients with Immune ThrombocytopeniaNew England Journal of Medicine, 2010
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007